# US 11,027,014 B2 · Methods using GDF-15 antibodies for treatment of pulmonary arterial hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,027,014 B2
- Document ID: US11027014B2
- Status: Granted
- Kind: B2
- Application number: 16/260,914
- Filed: 2019-01-29
- Published: 2019-12-05
- Granted: 2021-06-08
- Earliest claimed: 2014-08-01
- Assignees: The Brigham and Women's Hospital, Inc.
- Applicants: The Brigham and Women's Hospital, Inc.
- Inventors: Lai-Ming Yung; Paul B. Yu
- Web page: https://patentgrep.com/patent/US11027014B2

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 2039/505: {comprising antibodies}
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/495: Transforming growth factor [TGF]
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.

## Claims

### Claim 1

A method of treating pulmonary arterial hypertension (PAH) in a subject in need of treatment thereof, the method comprising administering a neutralizing antibody against Growth Differentiation Factor 15 (GDF-15) to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has scleroderma or connective tissue disease associated with PAH (APAH-CTD).

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is determined to have an increased level of GDF-15 relative to a control.